Business Information
The group's principal activity is to develop human therapeutic drugs using antisense and combinatorial technology. The antisense technology of the group create inhibitors or oligonucleotides, designed to hybridize or bind with high specificity to their rna target and modulate the production of proteins associated with diseases. It also uses antisense technology in collaborations with pharmaceutical companies to identify and prioritize attractive gene targets for their drug discovery programs. The group used antisense technology to commercialize its first product, vitravene. Vitravene is commerically available in the U.S., Europe, Australia and Brazil. The group uses ibis technology to design small molecule drugs that bind to rna through mechanisms other than hybridization.
|
|
Name |
Title
|
Email
|
| Stanley Crooke | Founder, Chmn., CEO | N/A | | David Ecker | Co - Founder, VP | N/A | | Frank Bennett | Sr. VP - Research | N/A | | Jeffrey Jonas | Exec. VP | N/A | | Lynne Parshall | Dir., Exec. VP, CFO, Sec. | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 24,532 | (45,903) | | 2005 | 40,133 | (72,401) | | 2004 | 42,624 | (142,503)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
